CL2017001599A1 - Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina - Google Patents
Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcinaInfo
- Publication number
- CL2017001599A1 CL2017001599A1 CL2017001599A CL2017001599A CL2017001599A1 CL 2017001599 A1 CL2017001599 A1 CL 2017001599A1 CL 2017001599 A CL2017001599 A CL 2017001599A CL 2017001599 A CL2017001599 A CL 2017001599A CL 2017001599 A1 CL2017001599 A1 CL 2017001599A1
- Authority
- CL
- Chile
- Prior art keywords
- trioxacarcin
- preparation
- analogs
- total synthesis
- synthesis
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 238000006257 total synthesis reaction Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094662P | 2014-12-19 | 2014-12-19 | |
| US201562186128P | 2015-06-29 | 2015-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001599A1 true CL2017001599A1 (es) | 2018-11-09 |
Family
ID=56127867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001599A CL2017001599A1 (es) | 2014-12-19 | 2017-06-19 | Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10899773B2 (enExample) |
| EP (1) | EP3233877A4 (enExample) |
| JP (1) | JP2017537968A (enExample) |
| KR (1) | KR20170122718A (enExample) |
| CN (1) | CN107250144A (enExample) |
| AU (1) | AU2015364347A1 (enExample) |
| BR (1) | BR112017013194A2 (enExample) |
| CA (1) | CA2970955A1 (enExample) |
| CL (1) | CL2017001599A1 (enExample) |
| CO (1) | CO2017007074A2 (enExample) |
| CR (1) | CR20170331A (enExample) |
| DO (1) | DOP2017000144A (enExample) |
| EA (1) | EA201791388A1 (enExample) |
| EC (1) | ECSP17046657A (enExample) |
| GT (1) | GT201700139A (enExample) |
| HK (1) | HK1243422A1 (enExample) |
| IL (1) | IL252947A0 (enExample) |
| MA (1) | MA41216A (enExample) |
| MX (1) | MX2017008162A (enExample) |
| PE (1) | PE20171787A1 (enExample) |
| PH (1) | PH12017501147A1 (enExample) |
| SG (1) | SG11201704935XA (enExample) |
| WO (1) | WO2016100833A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019036537A1 (en) * | 2017-08-17 | 2019-02-21 | William Marsh Rice University | ANALOGUES AND DIMER OF TRIOXACARCIN AS POWERFUL ANTICANCER AGENTS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815995A (ja) | 1981-07-22 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−４５−ａ↓１およびｄｃ−４５−ａ↓２ならびにそれらの製造法 |
| EP0157203A3 (en) * | 1984-04-04 | 1986-10-01 | American Cyanamid Company | Antitumor agents ll-d49194 alpha 1, ll-d49194 beta, ll-d49194 beta 2, ll-d49194 upsilon, ll-d49194 delta, ll-d49194 epsilon, ll-d49194 zeta, and ll-d49194 eta |
| JPS63135389A (ja) * | 1986-11-26 | 1988-06-07 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−４５類の誘導体 |
| US9102697B2 (en) | 2010-03-22 | 2015-08-11 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
| US9775915B2 (en) * | 2012-11-26 | 2017-10-03 | President And Fellows Of Harvard College | Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof |
-
2015
- 2015-12-17 MA MA041216A patent/MA41216A/fr unknown
- 2015-12-18 CR CR20170331A patent/CR20170331A/es unknown
- 2015-12-18 AU AU2015364347A patent/AU2015364347A1/en not_active Abandoned
- 2015-12-18 MX MX2017008162A patent/MX2017008162A/es unknown
- 2015-12-18 CA CA2970955A patent/CA2970955A1/en not_active Abandoned
- 2015-12-18 US US15/537,319 patent/US10899773B2/en active Active
- 2015-12-18 CN CN201580076346.2A patent/CN107250144A/zh active Pending
- 2015-12-18 PE PE2017001101A patent/PE20171787A1/es unknown
- 2015-12-18 EA EA201791388A patent/EA201791388A1/ru unknown
- 2015-12-18 BR BR112017013194-3A patent/BR112017013194A2/pt not_active Application Discontinuation
- 2015-12-18 HK HK18102899.8A patent/HK1243422A1/zh unknown
- 2015-12-18 EP EP15871176.2A patent/EP3233877A4/en not_active Withdrawn
- 2015-12-18 WO PCT/US2015/066703 patent/WO2016100833A2/en not_active Ceased
- 2015-12-18 JP JP2017532666A patent/JP2017537968A/ja not_active Withdrawn
- 2015-12-18 KR KR1020177020092A patent/KR20170122718A/ko not_active Withdrawn
- 2015-12-18 SG SG11201704935XA patent/SG11201704935XA/en unknown
-
2017
- 2017-06-15 IL IL252947A patent/IL252947A0/en unknown
- 2017-06-19 DO DO2017000144A patent/DOP2017000144A/es unknown
- 2017-06-19 GT GT201700139A patent/GT201700139A/es unknown
- 2017-06-19 PH PH12017501147A patent/PH12017501147A1/en unknown
- 2017-06-19 CL CL2017001599A patent/CL2017001599A1/es unknown
- 2017-07-14 CO CONC2017/0007074A patent/CO2017007074A2/es unknown
- 2017-07-19 EC ECIEPI201746657A patent/ECSP17046657A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20171787A1 (es) | 2017-12-28 |
| EA201791388A1 (ru) | 2017-11-30 |
| EP3233877A2 (en) | 2017-10-25 |
| IL252947A0 (en) | 2017-08-31 |
| MA41216A (fr) | 2017-10-24 |
| CA2970955A1 (en) | 2016-06-23 |
| WO2016100833A3 (en) | 2017-01-05 |
| BR112017013194A2 (pt) | 2018-01-02 |
| US10899773B2 (en) | 2021-01-26 |
| SG11201704935XA (en) | 2017-07-28 |
| GT201700139A (es) | 2018-10-24 |
| WO2016100833A2 (en) | 2016-06-23 |
| CO2017007074A2 (es) | 2017-10-20 |
| CN107250144A (zh) | 2017-10-13 |
| PH12017501147A1 (en) | 2018-03-05 |
| EP3233877A4 (en) | 2018-10-17 |
| JP2017537968A (ja) | 2017-12-21 |
| ECSP17046657A (es) | 2019-03-29 |
| MX2017008162A (es) | 2018-03-06 |
| KR20170122718A (ko) | 2017-11-06 |
| HK1243422A1 (zh) | 2018-07-13 |
| US20190023717A1 (en) | 2019-01-24 |
| DOP2017000144A (es) | 2017-09-29 |
| AU2015364347A1 (en) | 2017-07-13 |
| CR20170331A (es) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| CL2017001046A1 (es) | Inhibidoes del bromodominio | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| CL2015001990A1 (es) | Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos. | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| CO2017006214A2 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| CO2018003452A2 (es) | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso | |
| CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
| CL2015003200A1 (es) | Potenciador de inhibidores del homólogo de zeste | |
| MX2017010667A (es) | Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de unso. | |
| MX2018005528A (es) | Inhibidores de ret. | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| CL2016002509A1 (es) | Composiciones para modular la expresión de sod-1 | |
| CL2016000839A1 (es) | Composiciones para modular la expresión de c9orf72. | |
| CL2016003261A1 (es) | Formulación que comprende un profármaco de gemcitabina | |
| PE20150887A1 (es) | Compuestos de benceno sustituidos | |
| CL2015001392A1 (es) | Compuestos y sus métodos de empleo | |
| MX2015012456A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2021006734A (es) | Metodo para tratar el cancer. | |
| UY35469A (es) | Moduladores de p2x7 | |
| MX2016010296A (es) | Compuestos farmaceutios. | |
| BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
| BR112018005076A8 (pt) | Tratamento final extrativo de uma mistura de metanol-mma que contém sal de sódio |